Absence of the α2c-adrenoceptor Del322-325 allele is associated with increased mortality in patients with chronic systolic heart failure

Journal of Cardiac Failure

Volumn 18, Issue 12, 2012, Pages 925-929

  Amir, Offer ^a,b   Smith, Yoav ^c   Zafrir, Barak ^a,b   Azzam, Naiel ^d   Lewis, Basil S ^a   Fares, Fuad ^d  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b CARMEL MEDICAL CENTER   (Israel)

^c HEBREW UNIVERSITY   (Israel)

^d UNIVERSITY OF HAIFA   (Israel)

Author keywords

2c Del 322 325 polymorphism; Heart failure; mortality; norepinephrine

Indexed keywords

ALPHA 2C ADRENERGIC RECEPTOR;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; FEMALE; GENE DELETION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTOLIC HEART FAILURE;

ALLELES; BASE SEQUENCE; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HEART FAILURE, SYSTOLIC; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RECEPTORS, ADRENERGIC, ALPHA-2; SEQUENCE DELETION;

EID: 84870501570     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2012.10.013     Document Type: Article

References (27)

1. P. Dube, and K.T. Weber Congestive heart failure: pathophysiologic consequences of neurohormonal activation and the potential for recovery Am J Med Sci 342 2011 503 506
2. S.R. Goldsmith, P.A. Sobotka, and B.A. Bart The sympathorenal axis in hypertension and heart failure. The sympathorenal axis in hypertension and heart failure J Card Fail 16 2010 369 373
3. J.N. Cohn, T.B. Levine, M.T. Olivari, V. Garberg, D. Lura, and G.S. Francis Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure N Engl J Med 311 1984 819 823
4. O. Amir, R.E. Amir, H. Paz, R. Mor, M. Sagiv, and B.S. Lewis Aldosterone synthase gene polymorphism as a determinant of atrial fibrillation in patients with heart failure Am J Cardiol 102 2008 326 329
5. S. Cresci, R.J. Kelly, T.P. Cappola, A. Diwan, D. Dries, and S.L. Kardia Clinical and genetic modifiers of long-term survival in heart failure J Am Coll Cardiol 54 2009 432 444
6. O. Amir, R.E. Amir, H. Paz, E. Attias, M. Sagiv, and B.S. Lewis Relation between AT1R gene polymorphism and long-term outcome in patients with heart failure Cardiology 112 2009 151 157
7. M.D. Montgomery, and D.B. Bylund Lack of effect of the alpha2c-adrenoceptor Del322-325 polymorphism on inhibition of cyclic AMP production in HEK293 cells Br J Pharmacol 159 2010 820 830
8. K.M. Small, S.L. Forbes, F.F. Rahman, K.M. Bridges, and S.B. Liggett This four amino acid deletion polymorphism of the human 2c-adrenergic receptor confers impaired coupling to multiple effectors J Biol Chem 275 2000 23059 23064
9. K.M. Small, L.E. Wagoner, A.M. Levin, S.L. Kardia, and S.B. Liggett Synergistic polymorphisms of beta1- and alpha2c-adrenergic receptors and the risk of congestive heart failure N Engl J Med 347 2002 1135 1142
10. M.R. Bristow, G.A. Murphy, H. Krause-Steinrauf, J.L. Anderson, J.F. Carlquist, and S. Thaneemit-Chen An alpha2c-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure Circ Heart Fail 3 2010 21 28
11. S.L. Kardia, R.J. Kelly, M.A. Keddache, B.J. Aronow, G.A. Grabowski, and H.S. Hahn Multiple interactions between the alpha2c- and beta1-adrenergic receptors influence heart failure survival BMC Med Genet 9 2008 93 104
12. S. Nonen, H. Okamoto, M. Akino, Y. Matsui, Y. Fujio, and M. Yoshiyama No positive association between adrenergic receptor variants of alpha2cDel322-325, beta1Ser49, beta1Arg389 and the risk for heart failure in the Japanese population Br J Clin Pharmacol 60 2005 414 417
13. J. Du Preez, L.O. Matolweni, J. Greenberg, P. Mntla, A.A. Adeyemo, and B.M. Mayosi The alpha 2c Del322-325 adrenergic receptor polymorphism is not associated with heart failure due to idiopathic dilated cardiomyopathy in black Africans Cardiovasc J Afr 19 2008 15 16
14. J. Savva, A. Maqbool, H.L. White, S.L. Galloway, N.Y. Yuldasheva, S.G. Ball Merit-HF Study Group Polymorphisms of adrenoceptors are not associated with an increased risk of adverse event in heart failure: a MERIT-HF substudy J Card Fail 15 2009 435 441
15. V. Regitz-Zagrosek, B. Hocher, M. Bettmann, M. Brede, K. Hadamek, and C. Gerstner Alpha2c-adrenoceptor polymorphism is associated with improved event-free survival in patients with dilated cardiomyopathy Eur Heart J 27 2006 454 459
16. P.D. Sasieni From genotypes to genes: doubling the sample size Biometrics 53 1997 1253 1261
17. J.M. Bland, and D.G. Altman Statistics notes. The odds ratio BMJ 320 2000 1468 1470
18. Y. Sato, H. Suganami, C. Hamada, I. Yoshimura, H. Sakamoto, and T. Yoshida The confidence interval of allelic odds ratios under the Hardy-Weinberg disequilibrium J Hum Genet 51 2006 772 780
19. D. Rosskopf, and M.C. Michel Pharmacogenomics of G protein-coupled receptor ligands in cardiovascular medicine Pharmacol Rev 60 2008 513 535
20. A.J. Woodiwiss, D. Badenhorst, K. Sliwa, R. Brooksbank, R. Essop, and P. Sareli Beta1- and alpha2c-adrenoreceptor variants as predictors of clinical aspects of dilated cardiomyopathy in people of African ancestry Cardiovasc J Afr 19 2008 188 193
21. R. Gilsbach, M. Brede, N. Beetz, E. Moura, V. Muthig, and C. Gerstner Heterozygous alpha 2C-adrenoceptor-deficient mice develop heart failure after transverse aortic constriction Cardiovasc Res 75 2007 728 737
22. B.J. Materson, D.J. Reda, W.C. Cushman, B.M. Massie, E.D. Freis, and M.S. Kochar Single-drug therapy for hypertension in men - a comparison of six antihypertensive agents with placebo N Engl J Med 328 1993 914 921
23. ALLHAT Collaborative Research Group Officers and Coordinators Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 283 2000 1967 1975
24. J.N. Cohn, D.G. Archibald, S. Ziesche, J.A. Franciosa, W.E. Harston, and F.E. Tristani Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration cooperative study N Engl J Med 314 1986 1547 1552
25. J.N. Cohn, M.A. Pfeffer, J. Rouleau, N. Sharpe, K. Swedberg, and M. Straub MOXCON Investigators Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine inpatients with heart failure (MOXCON) Eur J Heart Fail 5 2003 659 667
26. M.R. Bristow, H. Krause-Steinrauf, R. Nuzzo, Liang Cheng-Seng, J. Lindenfeld, and B.D. Lowes Effect of baseline or changes in adrenergic activity on clinical outcomes in the Beta-Blocker Evaluation of Survival Trial (BEST) Circulation 110 2004 1437 1442
27. K.M. Small, J. Mialet-Perez, C.A. Seman, C.T. Theiss, K.M. Brown, and S.B. Liggett Polymorphisms of cardiac presynaptic alpha2c adrenergic receptors: Diverse intragenic variability with haplotype-specific functional effects Proc Natl Acad Sci U S A 101 2004 13020 13025